Drug Search Results
More Filters [+]

Ilorasertib

Alternative Names: ilorasertib, abt-348
Latest Update: 2023-09-13
Latest Update Note: News Article

Product Description

An orally bioavailable, adenosine triphospate mimetic, and inhibitor of Aurora kinases, vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor (PDGFRs), with potential antineoplastic activity. Upon administration, ilorasertib selectively binds to and inhibits Aurora kinases A, B and C, which may disrupt both the assembly of the mitotic spindle apparatus and chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. In addition, ilorasertib selectively binds to and inhibits VEGFRs and PDGFRs, which may result in the inhibition of both angiogenesis and tumor cell proliferation in VEGFR/PDGFR-overexpressing tumor cells. This agent also inhibits the Src family of cytoplasmic tyrosine kinases. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs are receptor tyrosine kinase families whose members may be upregulated in various tumor cell types. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ilorasertib)

Mechanisms of Action: AURK Inhibitor,VEGF Inhibitor,PGFR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ilorasertib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Mouth Cancer|Bone Cancer|Pregnancy Outcomes

Phase 1: Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Acute Lymphoid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Oncology Solid Tumor Unspecified|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2015-01251

P2

Terminated

Mouth Cancer|Pregnancy Outcomes|Bone Cancer

2022-05-12

IRB15-0083

P1

Completed

Oncology Solid Tumor Unspecified

2019-02-08

M10-944

P1

Completed

Oncology Solid Tumor Unspecified

2013-09-01

M10-943

P1

Completed

Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Myelodysplastic Syndrome|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Preleukemia|Acute Myeloid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia

2013-06-01

Recent News Events